丹奥、疏血通及松龄血脉康治疗脑梗塞合并高血压病疗效观察

Clinical Effect of Sodium Ozagrel,Shuxuetong Injection and Songlingxuemaikang on Cerebral Infarction with Hypertension

目的观察丹奥、疏血通注射液及松龄血脉康治疗脑梗塞合并高血压病的临床疗效。方法将87例脑梗塞合并高血压病患者随机分为治疗组和对照组,两组常规治疗相同,治疗组加用丹奥b id、疏血通qd,iv gtt,松龄血脉康tid,po;对照组以丹奥注射液b id,iv gtt;氨氯地平qd,po;2周后观察疗效。结果治疗组基本治愈15例(33.3%),显效17例(37.8%),好转11例(24.4%),无效2例(4.4%)。对照组基本治愈5例(11.9%),显效15例(35.7%),好转16例(38.1%),无效6例(14.3%)。两组比较显效率分别为71.11%和47.62%(P<0.05),有显著性差异;有效率为95.55%和85.71%(P>0.05),无显著性差异。结论治疗组用药方案优于对照组,安全度大,是临床一线治疗脑梗塞合并高血压病值得推广的方案。

Objective To investigate the clinical efficacy of sodium ozagrel and Shuxuetong for injection, Songlingxuemaikang orally in treating cerebral infarction patients with hypertension. Methods Eighty - seven cases of cerebral infarction patients with hypertension were divided into two groups at random,treatment group（45 cases） and control group（42 cases）. Both of the groups were treated with the same ordinary method. The treatment group was given sodium ozagrelbid, iv gtt,shuxuetong qd, iv gtt and songlingxuemaikang tid, po. The control group was given sodium ozagrel bid, iv gtt and Amlodipine qd, po. The treatment course was 2 weeks. Results The treatment group were basically cured for 15 cases （ 33.3% ）, marked effectiveness for 17 cases （37.8%）, better cffcctivcncss for 11 cases（24.4% ） ,no change for 2 cases（4.4% ）. In the control group, 5 cases were cured basically（11.9% ）, 15 cases were markedly effective （35.7%）, 16 cases were better （38. 1% ）, 6 cases were no change （ 14.3% ）. There was significant difference in a marked effective rate 71.11% and 47.62% （P 〈 0.05 ） but no significant difference in better effective rate 95. 554 and 85. 714 （P 〉0.05） between two groups. Conclusion The scheme of treatment group is better than the control group. It is safe and worth spreading in the clinic on cerebral infarction with hypertension.